Similarly, Yu et al. [38] recently identified a novel EH domain-binding protein 1-MET proto-oncogene receptor tyrosine kinase (EHBP1-MET) fusion by performing NGS analysis on both tumor tissue and ctDNA from a 41-year-old patient with iCCA; the patient was subsequently treated with MET inhibitor crizotinib and managed to achieve durable tumor response. This evidence concerns the gene MET and infantile convulsions and choreoathetosis.